Isomorphic Labs
London-based drug discovery company founded in 2021 as a Google DeepMind spinout, applying AI models built on AlphaFold to drug design, with collaborations with Novartis, Eli Lilly and Johnson & Johnson.
Industry: AI-driven drug discovery | Location: London, United Kingdom | Founded: 2021 | Total Funding: USD 2.7B
About Isomorphic Labs
Isomorphic Labs is an AI-driven drug discovery company founded in 2021 as a spinout from Google DeepMind, built to apply the technology behind AlphaFold, the protein structure prediction model, to drug design. It is led by Sir Demis Hassabis, whose stated ambition is to use AI to solve all disease. Directory listings place its headquarters in London, with offices in Lausanne, Switzerland, and Cambridge, Massachusetts. Headcount estimates vary widely between sources and the company has not published a firm figure. On 12 May 2026 the company announced a USD 2.1 billion Series B round led by Thrive Capital, which was making its second consecutive lead investment in the company. Existing backers Alphabet and GV returned, and new investors included MGX, Temasek, CapitalG and the UK Sovereign AI Fund. Sifted noted an earlier raise of USD 600 million in May 2025, and trackers put cumulative external capital at roughly USD 2.6 billion. MGX is the Abu Dhabi technology investment vehicle, and its participation fits a pattern of Gulf sovereign-linked capital backing frontier AI companies. The proceeds are intended to fund development of the company's drug design engine, known as IsoDDE, and to move its therapeutic programmes toward the clinic, along with hiring across London, Cambridge and Lausanne in AI, engineering, drug design and clinical disciplines. IsoDDE is described as a proprietary computational system, building on AlphaFold 3, that works across multiple therapeutic areas and modalities, predicting how candidate molecules interact with biological targets so they can be optimised before synthesis. The company's own pipeline targets structurally complex protein targets in oncology and immune-mediated disorders. Isomorphic has research collaborations with large pharmaceutical groups. In January 2024 it signed deals with Eli Lilly and Novartis focused on small-molecule discovery; Lilly's agreement carried USD 45 million upfront and up to USD 1.7 billion in milestones, and Novartis's USD 37.5 million upfront and up to USD 1.2 billion. In January 2026 it announced a cross-modality collaboration with Johnson & Johnson on which financial terms were not disclosed. No patient has yet been dosed with an Isomorphic-designed compound. Hassabis has said pre-clinical work has begun, and the company has said it plans to begin first-in-human trials by the end of 2026. Bloomberg reported in October 2026 that the company was in early talks to raise new capital at a valuation of at least USD 40 billion; that report is unconfirmed.
Leadership
- Demis Hassabis, Founder and Chief Executive Officer
- Demis Hassabis, Sir; leads Isomorphic Labs and CEO of Google AI
- Max Jaderberg, President
- Miles Congreve, Chief Scientific Officer
- Sarah Korman, Chief Business and Legal Officer
- Beverley Mallon, Chief People and Experience Officer
- Sarah Skerratt, Chief Research Officer
- Ben Wolf, Chief Medical Officer